Related Experiment Video
Updated: Jun 7, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block
Manel Esteller1,2,3,4
1Cancer Epigenetics Group, Josep Carreras Leukemia Research Institute (IJC), Barcelona, Catalonia, Spain.
Abstract:
In this article, Chen et al. show that a chemical modification of transfer RNA, along its corresponding RNA modifier enzyme, is diminished in acute myeloid leukaemia. These findings further support the role of an aberrant epitranscriptome in haematological malignancies. Commentary on: Chen et al. Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukemia. Br J Haematol 2025; 206:517-530.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Types of RNA
RNA Performs Diverse...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Leaky Scanning
Regulation of Expression at Multiple Steps

